NASDAQ:IMNN Imunon (IMNN) Stock Price, News & Analysis $1.32 -0.04 (-2.57%) (As of 10:33 AM ET) Add Compare Share Share Today's Range$1.33▼$1.4050-Day Range$1.06▼$1.5352-Week Range$0.48▼$2.00Volume5,315 shsAverage Volume126,523 shsMarket Capitalization$12.46 millionP/E RatioN/ADividend YieldN/APrice Target$12.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsShort InterestTrends Get Imunon alerts: Email Address Imunon MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside782.4% Upside$12.00 Price TargetShort InterestHealthy3.42% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($2.09) to ($1.64) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.10 out of 5 starsMedical Sector620th out of 879 stocksPharmaceutical Preparations Industry290th out of 417 stocks 3.5 Analyst's Opinion Consensus RatingImunon has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageImunon has only been the subject of 1 research reports in the past 90 days.Read more about Imunon's stock forecast and price target. Previous Next 4.0 Short Interest Percentage of Shares Shorted3.42% of the float of Imunon has been sold short.Short Interest Ratio / Days to CoverImunon has a short interest ratio ("days to cover") of 2.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Imunon has recently decreased by 1.89%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldImunon does not currently pay a dividend.Dividend GrowthImunon does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for IMNN. Previous Next 1.3 News and Social Media Coverage News SentimentImunon has a news sentiment score of -0.71. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.75 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Imunon this week, compared to 1 article on an average week.Search Interest2 people have searched for IMNN on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Imunon insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.00% of the stock of Imunon is held by insiders.Percentage Held by InstitutionsOnly 4.47% of the stock of Imunon is held by institutions.Read more about Imunon's insider trading history. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Imunon are expected to grow in the coming year, from ($2.09) to ($1.64) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Imunon is -0.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Imunon is -0.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioImunon has a P/B Ratio of 0.96. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Imunon's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Colonial MetalsThe asset beating inflation by 4xCentral Bank Gold Heist In Progress Central banks are buying gold at record rates... and billionaire investors are buying right along with them. Even Warren Buffett put over $500 million into gold. And with the help of a tax and penalty-free "Trump Loophole, " these investors are investing retirement into gold and other precious metals without having to put up any of their own cash. In our Free Retirement Protection Kit, we reveal all the details on how the rich use this loophole to protect and growth their retirement wealth in any economy…and show you how you can use it too.Click here to get your free copy today. About Imunon Stock (NASDAQ:IMNN)Imunon, Inc., a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company's lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development. Its preclinical stage products include IMNN-101, a COVID-19 booster vaccine; IMNN-102 for the treatment of Lassa virus; and IMNN-201, a Trp2 tumor associated antigen cancer vaccine in melanoma. In addition, the company develops non-viral DNA technology across four modalities, such as TheraPlas for the coding of proteins and cytokines in the treatment of solid tumors; PlaCCine for the coding of viral antigens that can elicit a strong immunological response; FixPlas for the application of Imunon's DNA technology to produce universal cancer vaccines; and IndiPlas, which is in the discovery phase for the development of personalized cancer vaccines or neoepitope cancer vaccines. Imunon, Inc. was formerly known as Celsion Corporation and changed its name to Imunon, Inc. in September 2022. The company was founded in 1982 and is headquartered in Lawrenceville, New Jersey.Read More IMNN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart IMNN Stock News HeadlinesJuly 7 at 1:18 AM | americanbankingnews.comImunon (NASDAQ:IMNN) versus Aileron Therapeutics (NASDAQ:ALRN) Critical ContrastJune 24, 2024 | globenewswire.comIMUNON Announces Database Lock for Phase 2 OVATION 2 Study with IMNN-001 in Advanced Ovarian CancerJuly 8, 2024 | Insiders Exposed (Ad)$5k to $1.3m in just 3 tradesIt doesn’t happen often, but occasionally, something completely unique comes across my radar. In this case, I’m talking about legal “Insider Trading”. Traders who have consistently signaled 453% … 610% .. and even 1036%... gains. And until now they have been doing it completely under the radar. In an upcoming interview I am revealing the strategy behind this gold-mine and how you can piggy back their every trade.June 5, 2024 | globenewswire.comFirst Participants Vaccinated in IMUNON's IMNN-101 Phase 1 Clinical TrialMay 16, 2024 | finance.yahoo.comIMNN: Results from OVATION 2 Study in Mid-2024…May 15, 2024 | uk.finance.yahoo.comQ1 2024 Imunon Inc Earnings CallMay 15, 2024 | finance.yahoo.comAbstract on Phase 2 Study with IMUNON’s IMNN-001 Plus Bevacizumab Accepted for Presentation at the American Society of Clinical Oncology Annual MeetingMay 15, 2024 | globenewswire.comAbstract on Phase 2 Study with IMUNON's IMNN-001 Plus Bevacizumab Accepted for Presentation at the American Society of Clinical Oncology Annual MeetingJuly 8, 2024 | Insiders Exposed (Ad)$5k to $1.3m in just 3 tradesIt doesn’t happen often, but occasionally, something completely unique comes across my radar. In this case, I’m talking about legal “Insider Trading”. Traders who have consistently signaled 453% … 610% .. and even 1036%... gains. And until now they have been doing it completely under the radar. In an upcoming interview I am revealing the strategy behind this gold-mine and how you can piggy back their every trade.May 14, 2024 | msn.comImunon, Inc. (NASDAQ:IMNN) Q1 2024 Earnings Call TranscriptMay 14, 2024 | uk.finance.yahoo.comImunon Inc (IMNN) Q1 2024 Earnings Call Transcript Highlights: Strategic Developments and ...May 13, 2024 | msn.comImunon GAAP EPS of -$0.52 beats by $0.05May 13, 2024 | globenewswire.comIMUNON Announces Site Activation for IMNN-101 Phase 1 Vaccine StudyMay 13, 2024 | globenewswire.comIMUNON Reports First Quarter 2024 Financial Results and Provides Business UpdateMay 8, 2024 | globenewswire.comIMUNON Appoints Director Dr. Stacy R. Lindborg as President and CEOMay 6, 2024 | globenewswire.comIMUNON to Hold First Quarter 2024 Financial Results and Business Update Conference Call on Monday, May 13, 2024April 28, 2024 | finance.yahoo.comImunon, Inc. (IMNN)April 18, 2024 | finance.yahoo.comIMUNON’s IND Application Cleared to Begin Human Testing of IMNN-101See More Headlines Receive IMNN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Imunon and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/13/2024Today7/08/2024Next Earnings (Estimated)8/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:IMNN CUSIPN/A CIK749647 Webwww.imunon.com Phone(609) 896-9100Fax609-896-2200Employees33Year FoundedN/APrice Target and Rating Average Stock Price Target$12.00 High Stock Price Target$12.00 Low Stock Price Target$12.00 Potential Upside/Downside+782.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($2.02) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-19,510,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-122.68% Return on Assets-84.15% Debt Debt-to-Equity RatioN/A Current Ratio2.51 Quick Ratio2.51 Sales & Book Value Annual Sales$500,000.00 Price / Sales25.58 Cash FlowN/A Price / Cash FlowN/A Book Value$1.42 per share Price / Book0.96Miscellaneous Outstanding Shares9,400,000Free Float8,931,000Market Cap$12.79 million OptionableNot Optionable Beta2.12 (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesMr. Michael H. Tardugno (Age 73)Executive Chairman Dr. Khursheed Anwer M.B.A. (Age 64)Ph.D., Executive VP & Chief Scientific Officer Comp: $632.26kMr. Timothy J. Tumminello CPA (Age 66)Chief Accounting Officer & Controller Comp: $108.31kDr. Sebastien Hazard M.D. (Age 52)Executive VP & Chief Medical Officer Key CompetitorsPluriNASDAQ:PLURNabriva TherapeuticsNASDAQ:NBRVLeap TherapeuticsNASDAQ:LPTXCalciMedicaNASDAQ:CALCCleneNASDAQ:CLNNView All Competitors IMNN Stock Analysis - Frequently Asked Questions How have IMNN shares performed this year? Imunon's stock was trading at $0.68 on January 1st, 2024. Since then, IMNN shares have increased by 100.0% and is now trading at $1.36. View the best growth stocks for 2024 here. How were Imunon's earnings last quarter? Imunon, Inc. (NASDAQ:IMNN) announced its quarterly earnings data on Monday, May, 13th. The company reported ($0.52) EPS for the quarter, topping analysts' consensus estimates of ($0.57) by $0.05. How do I buy shares of Imunon? Shares of IMNN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:IMNN) was last updated on 7/8/2024 by MarketBeat.com Staff From Our PartnersBiden to Launch “FedNOW” [Move Your Money Now]Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentia...Priority Gold | SponsoredWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | Sponsored50-year Wall Street Legend: “Prepare for a cash avalanche”The Dow crossed 40,000 for the first time in history… The S&P has hit over 30 all-time highs since the star...Chaikin Analytics | SponsoredObama wins Presidential debate When I said Obama would seek a third term… They called me a conspiracy theorist, they said it couldn’t happ...Porter & Company | SponsoredTrump’s Gift Could Unleash $51 Billion in New WealthIn January 2021, Donald Trump silently rolled out a special gift to the American public… One that top house...Wealthpin Pro | SponsoredNew Government Policy to Wipe Out Seniors WealthDon't wait until it's too late. The digital dollar is nearing the end of its trial period, and the window of o...Oasis Gold | SponsoredBiden Nomination CANCELED?And I believe when they do take the oath of office, their fingers will be crossed… and America will descend in...The Freeport Society | SponsoredNvidia’s Quiet $1 Trillion PivotNvidia recently added $277 billion in market cap … IN ONE DAY.Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Imunon, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Imunon With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.